Key Highlights
- Continued clinical activity in aesthetic and dermatology-focused devices
- Expansion into novel therapeutic applications, including neurodegenerative disease
- Growing use of comparative studies against established reference devices
- Increasing adoption of sham-controlled and non-inferiority trial designs
- Diversification across energy-based device categories (RF, radiation, laser)
The June 2026 MFDS medical device approvals reflect a broadening range of clinical applications for energy-based medical technologies. Although only three devices received approval during the month, each represents a distinct and notable direction within Korea’s medical device development landscape.
One approved study involved a general-purpose electrosurgical device evaluated for the temporary improvement of mild-to-moderate cheek wrinkles, compared against an established reference device, Thermage FLX. This reflects the continued strength of Korea’s aesthetic and dermatology device sector, where comparative, non-inferiority designs are increasingly used to benchmark new devices against recognized market leaders.
A second approved study evaluated HeLaXON, a low-dose therapeutic radiation device, in patients with mild Alzheimer’s disease dementia, assessing pre- and post-treatment changes through a sham-controlled exploratory design. This is a notable departure from typical device applications, suggesting growing interest in exploring energy-based devices for neurodegenerative disease indications where treatment options remain limited.
The third approved study involved a tri-wavelength, low-level laser (photobiomodulation) intranasal phototherapy device intended to relieve symptoms in patients with moderate persistent allergic rhinitis, evaluated through a sham device-controlled superiority design. This highlights continued innovation in non-invasive, light-based therapies for common ENT conditions.
Overall, the June 2026 approval data suggests that Korea’s medical device market continues to diversify across energy-based modalities, ranging from established aesthetic applications to early-stage exploration of novel therapeutic areas. Rigorous comparative and sham-controlled trial designs remain central to generating the clinical evidence needed to support these expanding applications.